Lung Cancer
Pipeline Insight: Lung Cancers Overview - Drugs Are Forecast To Realize Sales of Over $3.1 Billion By 2019
Published in Vaccine Weekly, February 9th, 2011
Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) remains poor. The late-phase pipeline holds little promise for considerable improvements in patient outcomes however; these drugs are forecast to realize sales of over $3.1 billion by 2019. Many unmet needs remain unfulfilled; therefore significant commercial opportunities...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2011-02-09)
More Articles from Vaccine Weekly
- Pediatric Vaccines
Data on Pediatric Vaccines Detailed by Researchers at University Hospital, Department of Medical Microbiology - Pediatric Vaccines
New study finds reminders for immunizations challenging for pediatric practices - Influenza Vaccines
Research from Eotvos Lorand University, Institute of Biology Broadens Understanding of Influenza Vaccines - Pediatric Vaccines
Research from University of Lagos, Medical Department Yields New Data on Pediatric Vaccines - Vaccines
UNICEF and Gates Foundation join forces to support Angola's efforts to eradicate polio - Diabetes
6 million euros for European Diabetes Research Network - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
